Literature DB >> 18412165

Epstein-Barr virus-induced gene 3 negatively regulates IL-17, IL-22 and RORgamma t.

Jianfei Yang1, Min Yang, Tin Min Htut, Xinshou Ouyang, Adedayo Hanidu, Xiang Li, Rosemarie Sellati, Huiping Jiang, Shu Zhang, Hongxing Li, Jie Zhao, Adrian T Ting, Lloyd Mayer, Jay C Unkeless, Mark E Labadia, Martin Hodge, Jun Li, Huabao Xiong.   

Abstract

Epstein-Barr virus-induced gene 3 (EBI3) associates with p28 to form IL-27 and with IL-12p35 to form IL-35. IL-27Ralpha(-/-) mice studies indicate that IL-27 negatively regulates Th17 cell differentiation. However, no EBI3, p28 or p35-deficiency studies that directly address the role of EBI3, p28 or p35 on Th17 cells have been done. Here, we demonstrate that spleen cells derived from EBI3(-/-) mice produce significantly higher levels of IL-17 as well as IL-22 upon stimulation with OVA. In vitro derived EBI3(-/-) Th17 cells also produced significantly higher levels of IL-17 and IL-22 than WT cells. The frequency of IL-17-producing cells was also elevated when EBI3(-/-) cells were cultured under Th17 conditions. In addition, spleen cells from EBI3(-/-) mice immunized with Listeria monocytogenes produced significantly elevated levels of IL-17 and IL-22. Furthermore, the Th17 transcription factor RORgamma t was significantly enhanced in EBI3(-/-) cells. Finally, EBI3(-/-) mice exhibited a reduced bacterial load following an acute challenge with L. monocytogenes or a re-challenge of previously immunized mice, suggesting that EBI3 negatively regulates both innate and adaptive immunity. Taken together, these data provide direct evidence that EBI3 negatively regulates the expression of IL-17, IL-22 and RORgamma t as well as protective immunity against L. monocytogenes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18412165      PMCID: PMC2989250          DOI: 10.1002/eji.200838145

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  35 in total

Review 1.  Th17: an effector CD4 T cell lineage with regulatory T cell ties.

Authors:  Casey T Weaver; Laurie E Harrington; Paul R Mangan; Maya Gavrieli; Kenneth M Murphy
Journal:  Immunity       Date:  2006-06       Impact factor: 31.745

2.  Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells.

Authors:  Estelle Bettelli; Yijun Carrier; Wenda Gao; Thomas Korn; Terry B Strom; Mohamed Oukka; Howard L Weiner; Vijay K Kuchroo
Journal:  Nature       Date:  2006-04-30       Impact factor: 49.962

3.  Disruption of T helper 2-immune responses in Epstein-Barr virus-induced gene 3-deficient mice.

Authors:  Edward E S Nieuwenhuis; Markus F Neurath; Nadia Corazza; Hideki Iijima; Joanne Trgovcich; Stefan Wirtz; Jonathan Glickman; Dan Bailey; Masaru Yoshida; Peter R Galle; Mitchell Kronenberg; Mark Birkenbach; Richard S Blumberg
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-13       Impact factor: 11.205

4.  Application of real-time polymerase chain reaction for the quantitation of interleukin-1beta mRNA upregulation in brain ischemic tolerance.

Authors:  X Li; X Wang
Journal:  Brain Res Brain Res Protoc       Date:  2000-04

5.  The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells.

Authors:  Ivaylo I Ivanov; Brent S McKenzie; Liang Zhou; Carlos E Tadokoro; Alice Lepelley; Juan J Lafaille; Daniel J Cua; Dan R Littman
Journal:  Cell       Date:  2006-09-22       Impact factor: 41.582

6.  Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system.

Authors:  Jason S Stumhofer; Arian Laurence; Emma H Wilson; Elaine Huang; Cristina M Tato; Leanne M Johnson; Alejandro V Villarino; Qiulong Huang; Akihiko Yoshimura; David Sehy; Christiaan J M Saris; John J O'Shea; Lothar Hennighausen; Matthias Ernst; Christopher A Hunter
Journal:  Nat Immunol       Date:  2006-08-13       Impact factor: 25.606

7.  Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells.

Authors:  Marcel Batten; Ji Li; Sothy Yi; Noelyn M Kljavin; Dimitry M Danilenko; Sophie Lucas; James Lee; Frederic J de Sauvage; Nico Ghilardi
Journal:  Nat Immunol       Date:  2006-08-13       Impact factor: 25.606

8.  WSX-1 is required for the initiation of Th1 responses and resistance to L. major infection.

Authors:  H Yoshida; S Hamano; G Senaldi; T Covey; R Faggioni; S Mu; M Xia; A C Wakeham; H Nishina; J Potter; C J Saris; T W Mak
Journal:  Immunity       Date:  2001-10       Impact factor: 31.745

9.  IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells.

Authors:  Stefan Pflanz; Jackie C Timans; Jeanne Cheung; Rency Rosales; Holger Kanzler; Jonathan Gilbert; Linda Hibbert; Tatyana Churakova; Marilyn Travis; Elena Vaisberg; Wendy M Blumenschein; Jeanine D Mattson; Janet L Wagner; Wayne To; Sandra Zurawski; Terrill K McClanahan; Daniel M Gorman; J Fernando Bazan; Rene de Waal Malefyt; Donna Rennick; Robert A Kastelein
Journal:  Immunity       Date:  2002-06       Impact factor: 31.745

10.  Protection from lethal septic peritonitis by neutralizing the biological function of interleukin 27.

Authors:  Stefan Wirtz; Ingrid Tubbe; Peter R Galle; Hans J Schild; Mark Birkenbach; Richard S Blumberg; Markus F Neurath
Journal:  J Exp Med       Date:  2006-07-31       Impact factor: 14.307

View more
  41 in total

Review 1.  A cytokine-centric view of the pathogenesis and treatment of autoimmune arthritis.

Authors:  Brian Astry; Erin Harberts; Kamal D Moudgil
Journal:  J Interferon Cytokine Res       Date:  2011-12       Impact factor: 2.607

Review 2.  Interleukin-35: Expanding Its Job Profile.

Authors:  Deepali V Sawant; Kristia Hamilton; Dario A A Vignali
Journal:  J Interferon Cytokine Res       Date:  2015-04-28       Impact factor: 2.607

Review 3.  Interleukin-35 in immune-related diseases: protection or destruction.

Authors:  Junfeng Zhang; Yunsheng Zhang; Qingpeng Wang; Chunlei Li; Hongxin Deng; Chuanping Si; Huabao Xiong
Journal:  Immunology       Date:  2019-03-07       Impact factor: 7.397

4.  IL-35 stimulation of CD39+ regulatory T cells confers protection against collagen II-induced arthritis via the production of IL-10.

Authors:  Irina Kochetkova; Sarah Golden; Kathryn Holderness; Gayle Callis; David W Pascual
Journal:  J Immunol       Date:  2010-05-10       Impact factor: 5.422

5.  IL-27 production and STAT3-dependent upregulation of B7-H1 mediate immune regulatory functions of liver plasmacytoid dendritic cells.

Authors:  Benjamin M Matta; Giorgio Raimondi; Brian R Rosborough; Tina L Sumpter; Angus W Thomson
Journal:  J Immunol       Date:  2012-04-16       Impact factor: 5.422

6.  Mechanisms of immunological tolerance in central nervous system inflammatory demyelination.

Authors:  Elisabeth R Mari; Jason N Moore; Guang-Xian Zhang; Abdolmohamad Rostami
Journal:  Clin Exp Neuroimmunol       Date:  2015-03-22

7.  Gene Expression and Antiviral Activity of Interleukin-35 in Response to Influenza A Virus Infection.

Authors:  Li Wang; Shengli Zhu; Gang Xu; Jian Feng; Tao Han; Fanpeng Zhao; Ying-Long She; Shi Liu; Linbai Ye; Ying Zhu
Journal:  J Biol Chem       Date:  2016-06-15       Impact factor: 5.157

8.  Levels of interleukin-35 and its relationship with regulatory T-cells in chronic hepatitis B patients.

Authors:  Yin-yue Shi; Ming-jia Dai; Gui-ping Wu; Pei-pei Zhou; Yuan Fang; Xue-bing Yan
Journal:  Viral Immunol       Date:  2014-12-10       Impact factor: 2.257

9.  Impact of Interleukin-27p28 on T and B Cell Responses during Toxoplasmosis.

Authors:  Jeongho Park; Jonathan H DeLong; James J Knox; Christoph Konradt; Elia D Tait Wojno; Christopher A Hunter
Journal:  Infect Immun       Date:  2019-11-18       Impact factor: 3.441

Review 10.  IL-27-induced modulation of autoimmunity and its therapeutic potential.

Authors:  Rakeshchandra R Meka; Shivaprasad H Venkatesha; Steven Dudics; Bodhraj Acharya; Kamal D Moudgil
Journal:  Autoimmun Rev       Date:  2015-08-05       Impact factor: 9.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.